These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 21403031)

  • 1. Primum non nocere.
    Kuhlmann D
    Arch Neurol; 2011 Mar; 68(3):397-8; author reply 398. PubMed ID: 21403031
    [No Abstract]   [Full Text] [Related]  

  • 2. Tapping into the biology of Alzheimer disease.
    Knopman DS
    Neurology; 2011 Feb; 76(6):496-7. PubMed ID: 21228299
    [No Abstract]   [Full Text] [Related]  

  • 3. Sharpen that needle.
    Herskovits AZ; Growdon JH
    Arch Neurol; 2010 Aug; 67(8):918-20. PubMed ID: 20697041
    [No Abstract]   [Full Text] [Related]  

  • 4. Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment.
    Riepe MW; Karl J; Tumani H; von Arnim CA
    Dement Geriatr Cogn Disord; 2010; 30(2):93-100. PubMed ID: 20720423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnosis of Alzheimer disease before it is Alzheimer dementia.
    Frisoni GB; Padovani A; Wahlund LO
    Arch Neurol; 2003 Jul; 60(7):1023; author reply 1023-4. PubMed ID: 12873864
    [No Abstract]   [Full Text] [Related]  

  • 6. Cerebrospinal fluid beta-amyloid and tau proteins for the diagnosis of Alzheimer disease.
    Knopman D
    Arch Neurol; 2001 Mar; 58(3):349-50. PubMed ID: 11255435
    [No Abstract]   [Full Text] [Related]  

  • 7. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
    Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
    Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
    Koric L; Felician O; Guedj E; Hubert AM; Mancini J; Boucraut J; Ceccaldi M
    Alzheimer Dis Assoc Disord; 2010; 24(3):278-83. PubMed ID: 20473135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.
    Bouwman FH; Verwey NA; Klein M; Kok A; Blankenstein MA; Sluimer JD; Barkhof F; van der Flier WM; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 30(1):1-7. PubMed ID: 20606438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tests for Alzheimer's disease.
    Health News; 2006 Jun; 12(6):2. PubMed ID: 16826618
    [No Abstract]   [Full Text] [Related]  

  • 15. New tests for AD.
    Health News; 2006 Apr; 12(4):15. PubMed ID: 16578901
    [No Abstract]   [Full Text] [Related]  

  • 16. Alzheimer's biomarker initiative hits its stride.
    Miller G
    Science; 2009 Oct; 326(5951):386-9. PubMed ID: 19833956
    [No Abstract]   [Full Text] [Related]  

  • 17. Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid.
    Talab R; Valis M; Rehak S; Krejsek J
    Neuro Endocrinol Lett; 2009; 30(5):647-51. PubMed ID: 20035270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory.
    Dumurgier J; Paquet C; Benisty S; Kiffel C; Lidy C; Mouton-Liger F; Chabriat H; Laplanche JL; Hugon J
    Neurobiol Dis; 2010 Nov; 40(2):456-9. PubMed ID: 20656030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.